Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 May 12;18(1):186.
doi: 10.1186/s12891-017-1543-z.

Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis

Shi-Qin Wang  1 , Li-Wei Zhang  1 , Pan Wei  1 , Hong Hua  2
Affiliations
Meta-Analysis

Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis

Shi-Qin Wang et al. BMC Musculoskelet Disord. .

Abstract

Background: To systematically review and assess the efficacy and safety of hydroxychloroquine (HCQ) for treating primary Sjogren's syndrome (pSS).

Methods: Five electronic databases (Pubmed, EMBASE, Web of science, Ovid, Cochrane Library) were searched for randomized controlled trials and retrospective or prospective studies published in English that reported the effect of HCQ on pSS. The subjective symptoms (sicca symptoms, fatigue and pain) and the objective indexes (erythrocyte sedimentation rate and Schirmer test) were assessed as main outcome measures. A meta-analysis and descriptive study on the efficacy and safety of HCQ were conducted. The estimate of the effect of HCQ treatment was expressed as a proportion together with 95% confidence interval, and plotted on a forest plot.

Results: Four trials with totals of 215 SS patients, including two randomized controlled trials, one double blind crossover trial and one retrospective open-label study, were analyzed in this review. For dry mouth and dry eyes, the effectiveness of HCQ treatment was essentially the same as placebo treatment. For fatigue, the effectiveness of HCQ was lower than placebo. The efficacy of HCQ in treating pain associated with pSS was superior to that of the placebo. There was no significant difference between HCQ-treated groups and controls in terms of Schirmer test results, but HCQ could reduce the erythrocyte sedimentation rate compare with placebo. A descriptive safety assessment showed that gastrointestinal adverse effects were the most common adverse effects associated with HCQ.

Conclusions: This systematic review showed that there is no significant difference between HCQ and placebo in the treatment of dry mouth and dry eye in pSS. Well-designed, randomized, controlled trials are needed to provide higher-quality evidence to confirm our findings, and future studies should focus on some other index or extraglandular measures, such as cutaneous manifestations, to further explore the therapeutic effect of HCQ in pSS.

Keywords: Hydroxychloroquine; Meta-analysis; Sjogren’s syndrome; Systematic review.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart showing the selection of articles
Fig. 2
Fig. 2
The efficacy of hydroxychloroquine treatment for dry mouth in primary Sjogren’s syndrome
Fig. 3
Fig. 3
The efficacy of placebo treatment for dry mouth in primary Sjogren’s syndrome
Fig. 4
Fig. 4
The efficacy of HQ treatment for dry eyes in primary Sjogren’s syndrome
Fig. 5
Fig. 5
The efficacy of placebo treatment for dry eyes in primary Sjogren’s syndrome
Fig. 6
Fig. 6
The efficacy of hydroxychloroquine treatment for pain in primary Sjogren’s syndrome
Fig. 7
Fig. 7
The efficacy of placebo treatment for pain in primary Sjogren’s syndrome
Fig. 8
Fig. 8
The efficacy of hydroxychloroquine treatment for fatigue in primary Sjogren’s syndrome
Fig. 9
Fig. 9
The efficacy of placebo treatment for fatigue in primary Sjogren’s syndrome
Fig. 10
Fig. 10
The pooled weighted mean difference of hydroxychloroquine versus placebo in erythrocyte sedimentation rate
Fig. 11
Fig. 11
The pooled weighted mean difference of hydroxychloroquine versus placebo in the Schirmer test
See this image and copyright information in PMC

References

    1. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37(2):217–229. doi: 10.1016/0030-4220(74)90417-4. - DOI - PubMed
    1. Fox PC. Autoimmune diseases and Sjogren’s syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:15–21. doi: 10.1196/annals.1384.003. - DOI - PubMed
    1. Espitia-Thibault A, Masseau A, Neel A, Espitia O, Toquet C, Mussini JM, Hamidou M. Sjogren’s syndrome-associated myositis with germinal centre-like structures. Autoimmun Rev. 2017;16(2):154–158. doi: 10.1016/j.autrev.2016.12.006. - DOI - PubMed
    1. Bolstad AI, Skarstein K. Epidemiology of Sjogren’s Syndrome-from an Oral Perspective. Curr Oral Health Rep. 2016;3(4):328–336. doi: 10.1007/s40496-016-0112-0. - DOI - PMC - PubMed
    1. ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren’s Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum. 2011;40(6):547–551. doi: 10.1016/j.semarthrit.2010.07.006. - DOI - PubMed

MeSH terms